OssDsign signs long-term contract with the largest hospital network in France to deliver unique patient specific cranial technology
Uppsala, March 22, 2022. OssDsign AB (publ.) today announces that the company has been awarded a long-term contract to deliver OssDsign Cranial PSI to the largest hospital network in France, Assistance Publique – Hôpitaux de Paris (AP-HP). Following competitive procurement rounds, OssDsign has been selected as one of two suppliers and will deliver its innovative cranioplasty product from April 1, 2022, until October 31, 2025.
Assistance Publique – Hôpitaux de Paris (AP-HP) is a world-renowned French university hospital organization that delivers care to 8.3 million individuals annually. Further, the network holds a number of prestigious clinical research institutions and represents more than 10% of the cranial surgery market in France. OssDsign has previously provided main AP-HP neurosurgery departments with its innovative cranioplasty product for test procedures as part of the tender process.
"We are very pleased to announce the agreement with AP-HP, which marks a noteworthy expansion of OssDsign’s commercial activity in France and the European market. As this is the largest and most prestigious contract in the French market, it is another clear recognition of the high quality and potential of our regenerative bone replacement technology," comments Morten Henneveld, CEO, OssDsign.
OssDsign currently has several established contracts in the French market. The attainment of a new large contract comes on top of the three substantial group purchasing agreements in the U.S. market, which the company won during the second half of 2021.
For further information, please contact:
Morten Henneveld, CEO, OssDsign AB
Tel: +46 73 382 43 90, email: morten.henneveld@ossdsign.com
Certified Adviser:
Erik Penser Bank AB is the company’s Certified Adviser. Contact information: Erik Penser Bank AB, Box 7405, 103 91 Stockholm, Sweden, phone: +46 (0)8-463 80 00, email: certifiedadviser@penser.se.
Om OssDsign
OssDsign is a developer and global provider of next generation bone replacement products. Based on cutting edge material science, the company develops and markets products that support the body’s own healing capabilities and thereby improve the clinical outcome in a wide range of orthopedic areas with high medical needs. With a product portfolio consisting of patient-specific implants for cranial surgeries and an off-the-shelf synthetic bone graft for spine surgeries, OssDsign give back patients the life they deserve. The company has a strong commercial presence in the U.S., Europe and selected Asian countries. OssDsign’s share is traded on Nasdaq First North Growth Market in Stockholm, Sweden.
Tags: